# A protective cGAMP-mediated anti-tumor immune response can proceed without LRRC8/VRAC channels

**Authors:** Fabian M.B. Thöne, Maya M. Polovitskaya, Uta E. Höpken, Armin Rehm, Thomas J. Jentsch

PMC · DOI: 10.1016/j.jbc.2025.111060 · 2025-12-17

## TL;DR

The study shows that a key immune response against tumors can happen without specific cell channels called VRAC, even though these channels can transport an important immune molecule called cGAMP.

## Contribution

Demonstrates that antitumor immunity via cGAMP does not require LRRC8/VRAC channels in tumor or host cells.

## Key findings

- Tumor-produced cGAMP significantly suppresses tumor growth.
- Antitumor immune response is independent of VRAC channels in both tumor and host cells.
- Disruption of LRRC8B–LRRC8E subunits does not affect T or B cell development.

## Abstract

The volume-regulated anion channel (VRAC) is a hetero-hexamer composed of LRRC8A and any of the four other LRRC8 paralogs (LRRC8B–E). Depending on their subunit composition, VRACs not only transport chloride, but also a range of organic substrates including 2′3′-cGAMP (cGAMP). Transfer of this immunomodulator from tumor to host cells is critical for antitumor immunity. Whether this process depends on VRAC in vivo remains incompletely understood. To address this issue, we studied subcutaneous MC38 and B16-F10 tumors in syngeneic mice. Enhanced growth of MC38 tumors lacking cGAMP production confirmed the importance of tumor-produced cGAMP. The impact of VRAC-mediated cGAMP-efflux from tumor cells and its uptake into cells of the tumor microenvironment was investigated using LRRC8A-deficient tumor cells and recipient mice with selective LRRC8 subunit disruptions, respectively. Changed serum cytokines indicated moderate immunomodulatory effects of VRAC-mediated cGAMP export from MC38 tumors. However, tumor growth and the cGAMP-mediated antitumor immune response were independent of both tumor- and host-expressed VRAC. Disruption of any of the non-essential subunits, LRRC8B–LRRC8E, had no discernible effect on T or B cell development in mice. While tumor-produced cGAMP markedly suppresses tumor growth, transport of this immunomodulator to the tumor environment primarily involves transporters distinct from VRAC.

## Linked entities

- **Genes:** LRRC8A (leucine rich repeat containing 8 VRAC subunit A) [NCBI Gene 56262], LRRC8B (leucine rich repeat containing 8 VRAC subunit B) [NCBI Gene 23507], LRRC8C (leucine rich repeat containing 8 VRAC subunit C) [NCBI Gene 84230], LRRC8D (leucine rich repeat containing 8 VRAC subunit D) [NCBI Gene 55144], LRRC8E (leucine rich repeat containing 8 VRAC subunit E) [NCBI Gene 80131]
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Lrrc8e (leucine rich repeat containing 8 family, member E) [NCBI Gene 72267] {aka 1810049O03Rik}, Lrrc8b (leucine rich repeat containing 8 family, member B) [NCBI Gene 433926] {aka 2210408K08Rik, Ta-lrrp, mKIAA0231}, Lrrc8a (leucine rich repeat containing 8A VRAC subunit A) [NCBI Gene 241296] {aka Lrrc8, SWELL1, ebo, mKIAA1437}
- **Diseases:** tumor (MESH:D009369)
- **Chemicals:** cGAMP (MESH:C584311), chloride (MESH:D002712), 2'3'-cGAMP (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12828768/full.md

---
Source: https://tomesphere.com/paper/PMC12828768